FIELD: biotechnology.
SUBSTANCE: invention relates to a non-human animal containing a genetically modified endogenous Asgr1 locus that contains an endogenous Asgr1 promoter, wherein the non-human animal is a rodent and the endogenous Asgr1 promoter is operably linked to a nucleic acid encoding modified Asgr1 protein, modified Asgr1 protein contains a cytoplasmic domain, a transmembrane domain and an extracellular domain, the extracellular domain contains a supercoiled domain.
EFFECT: invention is effective for evaluating delivery of a therapeutic complex to the liver via human ASGR1-mediated internalization in vivo, as well as for evaluating the effectiveness of a therapeutic molecule for protein targeting in relation to liver internalization via human ASGR1 in vivo.
31 cl, 9 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NON-HUMAN ANIMALS EXPRESSING HUMANISED COMPLEX CD3 | 2015 |
|
RU2726446C2 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED TrkB LOCUS | 2018 |
|
RU2800428C2 |
| ANIMALS OTHER THAN HUMANS HAVING A HUMANISED CLUSTER GENE OF DIFFERENTIATION 47 | 2015 |
|
RU2728412C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| ANIMALS OTHER THAN HUMANS, HAVING HUMANISED DIFFERENTIATION CLUSTER GENE 47 | 2015 |
|
RU2827833C1 |
| NON-HUMAN ANIMALS CONTAINING HUMANISED ALBUMIN LOCUS | 2020 |
|
RU2815514C2 |
| HUMANIZED MICE WITH SIRPA-IL15 KNOCKIN AND METHODS OF USE THEREOF | 2016 |
|
RU2822370C2 |
| DITRA MODELS IN NON-HUMAN ANIMALS AND THEIR USE | 2019 |
|
RU2804448C2 |
| RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2811426C2 |
